Dyne Therapeutics Inc DYN 深 滬
等待開盤 06-26 09:30:00 美东时间
20.61
+0.280
+1.38%
華盛通- 最 高21.255
- 今 開20.31
- 成交量 162.76万股
- 最 低 20.25
- 昨 收 20.33
- 總市值 34.07亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.98%
- 52周最低 8.06
- 委 比 23.10%
- 總股本 1.65亿
- 歷史最高 47.45
- 量 比 0.53
- 振 幅 4.94%
- 歷史最低 4.30
- 每 手 1
- 風險率 3.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyne Therapeutics expands Hercules Capital debt facility to up to $400 million
Dyne Therapeutics expands Hercules Capital debt facility to up to $400 million Dyne Therapeutics amended its senior secured term loan facility with Hercules Capital, expanding total capacity to up to $400 million. The amendment funded $50 million at closing, lifting total borrowings under the facili
06-17 19:35
Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basivarsen In Individuals With DM1
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused
06-03 19:34
Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1
Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1 Dyne Therapeutics completed enrollment in a 71-participant registrational expansion cohort of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1. Results have not been presented; topline data are schedu
06-03 19:30
Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment -- Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary
05-20 19:49
Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy
Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen for Duchenne muscular dystrophy patients eligible for exon 51 skipping, positioning the study as the confirmatory program for a planned U.S. a
05-20 19:46
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Dyne Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Dyne Therapeutics shares are trading higher after the company reported better-t...
05-11 22:58
Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of $(1.05) per share from
05-11 19:40
Dyne to present DELIVER, ACHIEVE trial data at AMCP as it readies US DMD launch
Dyne to present DELIVER, ACHIEVE trial data at AMCP as it readies US DMD launch Dyne Therapeutics flagged three poster presentations at AMCP 2026 in Nashville, set for April 13-16, covering Duchenne muscular dystrophy and myotonic dystrophy type 1. Previously shared positive results from Dyne’s DELI
04-01 19:31
